Rothblatt Reports United Therapeutics Ownership Change

TL;DR

**Martine Rothblatt just reported a change in her United Therapeutics holdings.**

AI Summary

This Form 4 filing indicates that Martine A. Rothblatt, a reporting insider, had a change in beneficial ownership of securities in United Therapeutics Corp. as of March 23, 2026. While the filing itself doesn't detail the transaction (buy/sell/grant), it signals an insider's activity. For investors, this matters because insider transactions can sometimes signal management's confidence (or lack thereof) in the company's future prospects, potentially influencing stock price.

Why It Matters

Insider activity can provide clues about a company's health and future, as those closest to the business often have the most insight.

Risk Assessment

Risk Level: low — This filing is purely administrative, reporting a change in ownership, and does not inherently carry significant risk without transaction details.

Analyst Insight

An investor should look for the detailed transaction information within the full Form 4 document to understand if Martine A. Rothblatt bought or sold shares, and in what quantity, to gauge potential implications for United Therapeutics Corp. stock.

Key Players & Entities

• Martine A. Rothblatt (person) — Reporting insider
• United Therapeutics Corp. (company) — Issuer of securities
• 0001106578 (other) — CIK for Martine A. Rothblatt
• 0001082554 (other) — CIK for United Therapeutics Corp.

FAQ

Key Financial Figures

• $517.81 — multiple trades at prices ranging from $517.81 to $518.60. The price reported above re
• $518.60 — rades at prices ranging from $517.81 to $518.60. The price reported above reflects the
• $518.89 — multiple trades at prices ranging from $518.89 to $519.87. The price reported above re
• $519.87 — rades at prices ranging from $518.89 to $519.87. The price reported above reflects the
• $519.97 — multiple trades at prices ranging from $519.97 to $520.89. The price reported above re
• $520.89 — rades at prices ranging from $519.97 to $520.89. The price reported above reflects the
• $520.99 — multiple trades at prices ranging from $520.99 to $521.97. The price reported above re
• $521.97 — rades at prices ranging from $520.99 to $521.97. The price reported above reflects the
• $522.06 — multiple trades at prices ranging from $522.06 to $522.29. The price reported above re
• $522.29 — rades at prices ranging from $522.06 to $522.29. The price reported above reflects the
• $523.74 — multiple trades at prices ranging from $523.74 to $524.49. The price reported above re
• $524.49 — rades at prices ranging from $523.74 to $524.49. The price reported above reflects the
• $524.98 — multiple trades at prices ranging from $524.98 to $525.94. The price reported above re
• $525.94 — rades at prices ranging from $524.98 to $525.94. The price reported above reflects the
• $526.12 — multiple trades at prices ranging from $526.12 to $526.84. The price reported above re

Filing Documents

• primarydocument.html (4)
• primarydocument.xml (4) — 41KB
• 0001106578-26-000018.txt ( ) — 43KB

From the Filing

SEC FORM 4 SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). X Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. 1. Name and Address of Reporting Person * ROTHBLATT MARTINE A (Last) (First) (Middle) C/O UNITED THERAPEUTICS CORPORATION 1000 SPRING STREET (Street) SILVER SPRING MARYLAND 20910 (City) (State) (Zip) UNITED STATES (Country) 2. Issuer Name and Ticker or Trading Symbol UNITED THERAPEUTICS Corp [ UTHR ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner X Officer (give title below) Other (specify below) Chairperson & CEO 2a. Foreign Trading Symbol 3. Date of Earliest Transaction (Month/Day/Year) 03/23/2026 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person 4. If Amendment, Date of Original Filed (Month/Day/Year) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 03/23/2026 M (1) 9,500 A $ 146.03 50,013 D Common Stock 03/23/2026 S (1) 240 D $ 518.3888 (2) 49,773 D Common Stock 03/23/2026 S (1) 906 D $ 519.289 (3) 48,867 D Common Stock 03/23/2026 S (1) 867 D $ 520.5399 (4) 48,000 D Common Stock 03/23/2026 S (1) 1,320 D $ 521.3755 (5) 46,680 D Common Stock 03/23/2026 S (1) 160 D $ 522.19 (6) 46,520 D Common Stock 03/23/2026 S (1) 647 D $ 524.1477 (7) 45,873 D Common Stock 03/23/2026 S (1) 400 D $ 525.4325 (8) 45,473 D Common Stock 03/23/2026 S (1) 640 D $ 526.5854 (9) 44,833 D Common Stock 03/23/2026 S (1) 120 D $ 527.574 (10) 44,713 D Common Stock 03/23/2026 S (1) 342 D $ 529.8009 (11) 44,371 D Common Stock 03/23/2026 S (1) 703 D $ 530.9129 (12) 43,668 D Common Stock 03/23/2026 S (1) 671 D $ 531.6541 (13) 42,997 D Common Stock 03/23/2026 S (1) 364 D $ 533.1517 (14) 42,633 D Common Stock 03/23/2026 S (1) 920 D $ 533.932 (15) 41,713 D Common Stock 03/23/2026 S (1) 830 D $ 535.1189 (16) 40,883 D Common Stock 03/23/2026 S (1) 370 D $ 536.1568 (17) 40,513 D Common Stock 166 I by Spouse Common Stock 324,518 I by Trust (18) Common Stock 258,117 I by Trust (19) Common Stock 45,596 I by Trust (20) Common Stock 10,962 I by Trust (21) Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Option $ 146.03 03/23/2026 M (1) 9,500 03/15/2020 03/15/2027 Common Stock 9,500 $ 0.00 88,000 D Explanation of Responses: 1. This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026. 2. This transaction was executed in multiple trades at prices ranging from $517.81 to $518.60. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and pr

View Full Filing

View this 4 filing on SEC EDGAR